RISK FACTORS

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

difficulty of ensuring that third-party partners do not infringe, misappropriate, or
otherwise violate the patent, trade secret, or other intellectual property rights of
others;

unexpected changes in or imposition of trade restrictions, such as tariffs, sanctions
or other trade controls, and similar regulatory requirements;

economic weakness, including inflation;

compliance with tax, employment,
traveling abroad;

immigration and labor laws for employees

the effects of applicable foreign tax structures and potentially adverse tax
consequences;

currency fluctuations, which could result
reduced revenue;

in increased operating expenses and

workforce uncertainty and labor unrest;

failure of our employees and contracted third parties to comply with United States
Department of the Treasury’s Office of Foreign Assets Control rules and regulations
and the United States Foreign Corrupt Practices Act of 1977, as amended, or FCPA;
and

business interruptions resulting from geo-political actions, including war and acts of
terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods,
hurricanes and fires.

These and other risks may materially adversely affect our ability to procure equipment

and raw material and to attain or sustain any future revenue from international markets.

Risks Relating to Our Intellectual Property Rights

If we are unable to obtain and maintain patent protection for our drug candidates through
intellectual property rights, or if the scope of such intellectual property rights obtained is not
sufficiently broad, third parties could develop and commercialize products and technologies
similar or identical to ours and compete directly against us, and our ability to successfully
commercialize any product or technology may be adversely affected.

Our success depends in large part on our ability to protect our proprietary technology and
drug candidates from competition by obtaining, maintaining, defending and enforcing our
intellectual property rights, including patent rights. We seek to protect the drug candidates and
technology that we consider commercially important by filing patent applications in the United
States, China and other countries, relying on trade secrets or pharmaceutical regulatory

– 77 –

